In short
Clinical trials are investigating Melphalan in several cancers and blood disorders. These studies look at safety, effectiveness, and longer-term outcomes in groups such as patients with multiple myeloma, leukemia, neuroblastoma, sarcoma, and metastatic cancer. The trials include different phases and treatment settings, including transplant preparation, consolidation therapy, and disease control.
Key points
- Clinical trials of Melphalan are studying a wide range of cancers and blood diseases, including multiple myeloma, leukemia, neuroblastoma, sarcoma, retinoblastoma, and metastatic solid tumors. The studies include Phase 1/2, Phase 2, Phase 3, and Phase 4 trials, so they range from early safety work to larger comparison studies. Many trials use Melphalan as part of combination treatment, transplant conditioning, or local therapy. The target groups vary from children and adolescents to adults and older adults, including patients with high-risk, relapsed, or transplant-related disease. Main outcomes include survival measures, disease control, toxicity, and organ preservation.
Clinical trials overview
These studies are looking at Melphalan in different cancer and transplant settings. The trials are designed to test safety, treatment effect, and longer-term results in patients with blood cancers, solid tumors, and eye cancers.
The trial designs are mostly interventional, which means the research team gives a treatment plan and measures the results. The studies include both completed and authorised trials, with phases ranging from Phase 1/2 to Phase 4.
Conditions studied with Melphalan
Melphalan appears in trials for several diseases, including multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, neuroblastoma, Ewing Sarcoma, retinoblastoma, metastatic colorectal cancer, metastatic breast cancer, uveal melanoma, and Langerhans Cell Histiocytosis.
Some studies focus on disease that is high-risk, relapsed, refractory, or resistant, which means the cancer is harder to treat or has come back after earlier therapy. Other trials look at Melphalan in transplant preparation or as part of consolidation treatment after the first phase of therapy.
Who can take part
The target populations vary a lot from trial to trial. Some trials include children and adolescents, such as studies in acute myeloid leukemia, neuroblastoma, retinoblastoma, and Langerhans Cell Histiocytosis.
Other studies focus on adults with relapsed or refractory lymphoma, metastatic cancer, or blood cancers, and some are limited to older adults or people who are not eligible for autologous stem cell transplant. Several transplant studies include patients with AML or MDS undergoing allogeneic transplantation or reduced intensity conditioning.
Some trials also require a specific risk group, such as high-risk or very high-risk disease, or a specific disease state like first or second complete remission in AML.
Trial phases and main endpoints
The phase of a trial shows how advanced the study is. Phase 2 studies often look at safety and early signs of effect, while Phase 3 studies compare treatment strategies in larger groups. The Phase 1/2 study in uveal melanoma is designed to find safe dosing and then test early efficacy.
Common endpoints include overall survival, progression-free survival, event-free survival, and failure-free survival. Some trials also measure toxicity, adverse events, serious adverse events, and specific disease response measures such as metastatic response or ocular preservation.
For example, one Ewing Sarcoma study measures the frequency, duration, and severity of adverse effects and serious adverse effects, plus event-free survival at 36 months. Another transplant study measures toxicity using the Bearman Scale and NCI CTCAE v5.0, and also looks at 2-year progression-free survival.
How Melphalan is being used in the trials
Melphalan is usually part of a larger treatment plan rather than a stand-alone treatment. In some trials it is used with other drugs such as fludarabine, treosulfan, busulfan, or cyclophosphamide in transplant conditioning, which means treatment given before stem cell transplant to prepare the body.
In other studies, Melphalan is combined with chemotherapy, immunotherapy, or local procedures. Examples include high-dose regional treatment for liver-dominant metastatic disease, combination therapy in neuroblastoma, and intravitreal or intra-arterial use in retinoblastoma.
Some studies compare one Melphalan-based strategy with another treatment strategy. For example, the RELEVANT trial compares treosulfan-based conditioning with Melphalan-based conditioning in AML and MDS, while the multiple myeloma trial in older adults compares standard treatment with experimental treatment plans that include Melphalan.
Key studies at a glance
The largest studies in this data set are in neuroblastoma, acute myeloid leukemia, and precision medicine in cancer, but only some of them use Melphalan as a study drug. The most direct Melphalan-focused trials include transplant conditioning studies, high-risk neuroblastoma studies, multiple myeloma studies, and studies of liver-dominant metastatic disease.
- High-risk Ewing Sarcoma study: tests Treosulfan/Melphalan consolidation and measures safety plus 36-month event-free survival.
- Transplant preparation study in AML or MDS: uses Melphalan with fludarabine and other agents, and measures toxicity and 2-year progression-free survival.
- RELEVANT trial: compares Melphalan-based conditioning with treosulfan-based conditioning in allogeneic transplant patients with AML or MDS, using overall survival as the main outcome.
- High-risk neuroblastoma phase 3 study: includes a Melphalan-containing high-dose chemotherapy arm and measures 3-year event-free survival.
- Retinoblastoma study: uses Melphalan by intra-arterial or intravitreal routes and measures eye preservation without external beam radiotherapy.
- Metastatic colorectal and breast cancer studies: test Melphalan-based liver-directed treatment followed by other systemic therapy and measure hepatic progression-free survival.